A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis

Trial Profile

A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Piclidenoson (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACROBAT
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 30 May 2017 According to a Can-Fite BioPharma media release, the company expects to commence this trial by the third quarter of 2017.
    • 16 May 2017 According to a Can-Fite BioPharma media release, the company has filed a Clinical Trial Application (CTA) with Health Canada for the commencement of patient enrollment in Canada.
    • 25 Apr 2017 According to a Can-Fite BioPharma media release, Barzilai Medical Center's Institutional Review Board (IRB) has approved this Phase III ACRobat trial protocol and patient enrollment for the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top